Murex anti-HCV (version 4.0)*
ELISA Infectious disease

■ Technical Assay Details

<table>
<thead>
<tr>
<th>Article Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7F51-01</td>
<td>96 tests, 1 plate, non C marked</td>
</tr>
<tr>
<td>7F51-02</td>
<td>480 tests, 5 plates, non C marked</td>
</tr>
<tr>
<td>7F51-06</td>
<td>96 tests, 1 plate, C marked</td>
</tr>
<tr>
<td>7F51-07</td>
<td>480 tests, 5 plates, C marked</td>
</tr>
</tbody>
</table>

Microplate Coating: Highly purified antigens representing core, NS3, NS4 and NS5
Incubation Time: 60 min sample / 30 min conjugate / 30 min substrate (total 2.0 hours)
Incubation Temp.: 37°C / 37°C / 37°C (± 1°C each)
Assay Volumes: 180 μl diluent / 20 μl sample / 100 μl conjugate
100 μl TMB substrate / 50 μl stop solution
Wash Steps: Two wash steps with 5x washes each.
Each wash using 500 μl / well of wash buffer.

■ Quality Control and Cut Off Criteria

Controls (C): The kit includes Negative and Positive controls.
Each run requires:
– 1 Negative control well
– 1 Positive control well
QC Neg. Cont. (NC value): Mean Value of NC < 0.25 OD (optical density)
QC Pos. Cont. (PC value): Mean Value of PC > 0.8 OD than mean value of NC
Cut off Definition: Mean value of NC + 0.6 OD
Results Interpretation: OD value of the sample < cut off (non-reactive)
OD value of the sample ≥ cut off (initially reactive)

■ Assay Performance

Specificity:
A total of 8835 samples from blood donors were analyzed in Europe and Australia. Initial and repeat reactive rates were 0.18% (16/8835) and 0.12% (11/8835) respectively. The specificity of Murex anti-HCV (version 4.0) on this population of presumed negative samples is estimated to be 99.88% (8824/8835), with a 95% confidence interval of 99.77 to 99.94%.

Sensitivity:
A total of 69 samples with antibody to HCV, confirmed with an alternative Immunoassay (Western blot), were reactive with Murex anti-HCV (version 4.0). The diagnostic sensitivity of the Murex anti-HCV assay on this population of specimens was observed to be 100% (69/69), with a lower 95% confidence limit of 94.79%.

* = only for special destinations
**Murex anti-HCV (version 4.0)**

**ELISA Infectious disease**

### Assay Principle

Antibody sandwich 3rd generation ELISA

### Your Advantages

- **High security** for the operator with dispense monitoring for all steps.
- **Ease of use** by performing the Murex anti-HCV (version 4) assay in manual, semi-automated or fully automated way.
- **Less extra work**, because of a low rate of repeat reactive samples.
- **Optimal specificity** using highly purified and recombinant antigens and peptides.
- **Ideally used as an HCV confirmation assay** when it is done together with the Murex HCV Ag/Ab Combination* assay (Art. No. 4J24).
- **High sensitivity**: earlier detection compared to other tests on seroconversion panels.
- **Detection** of all major HCV genotypes.

* = only for special destinations

---

DiaSorin S.p.A.
Via Crescentino
13040 Saluggia (VC), Italy
Tel. +39.0161.487526
Fax: +39.0161.487670
www.diasorin.com
E-mail: info@diasorin.it